| Identification | Back Directory | [Name]
4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-N-(2-methyl-1-(2-(1-methylpiperidin-4-yl)phenyl)propan-2-yl)-6-morpholino-1,3,5-triazin-2-amine | [CAS]
1401436-95-0 | [Synonyms]
PWT-143
EOS-60789
Zandelisib
4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-N-(2-methyl-1-(2-(1-methylpiperidin-4-yl)phenyl)propan-2-yl)-6-morpholino-1,3,5-triazin-2-amine
1,3,5-Triazin-2-amine, 4-[2-(difluoromethyl)-1H-benzimidazol-1-yl]-N-[1,1-dimethyl-2-[2-(1-methyl-4-piperidinyl)phenyl]ethyl]-6-(4-morpholinyl)- | [Molecular Formula]
C31H38F2N8O | [MDL Number]
MFCD32710288 | [MOL File]
1401436-95-0.mol | [Molecular Weight]
576.68 |
| Chemical Properties | Back Directory | [Boiling point ]
729.2±70.0 °C(Predicted) | [density ]
1.33±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 33.33 mg/mL (57.80 mM; ultrasonic and warming and adjust pH to 3 with HCl and heat to 60°C) | [form ]
Solid | [pka]
8.97±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Zandelisib (ME-401) is a phosphatidylinositol 3-kinase (PI3K) inhibitor extracted from patent WO2019183226 A1, Compound Example 1. Zandelisib selectively inhibits p110δ with an IC50 of 3.5 nM. Zandelisib functions as an antineoplastic[1][2]. | [IC 50]
PI3Kδ: 3.5 nM (IC50) | [storage]
Store at -20°C | [References]
[1] Daniel P. Gold, et al. Combination therapy. WO2019183226A1.
[2] David Brown, et al. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases. WO2014055647A1. |
|
|